Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7107957 | 0.85 | CYP1A2 (0.52) | CYP1A2TDP1LMNAHTTALDH1A1 | |
| SCHEMBL7107955 | 0.85 | CYP1A2 (0.52) | CYP1A2TDP1LMNAHTTALDH1A1 | |
| SCHEMBL1635965 | 0.81 | CYP1A2 (0.49) | CYP1A2TDP1LMNAALDH1A1GAA | |
| SCHEMBL19897547 | 0.76 | SRC (0.36) | CYP1A2TDP1LMNAALDH1A1MAPT | |
| SCHEMBL27849268 | 0.76 | LMNA (0.46) | CYP1A2TDP1LMNAHTTALDH1A1 | |
| SCHEMBL1760762 | 0.74 | CYP1A2 (0.52) | CYP1A2TDP1AHRHTR2AMAOB | |
| SCHEMBL1760765 | 0.74 | CYP1A2 (0.52) | CYP1A2TDP1AHRHTR2AMAOB | |
| SCHEMBL28184213 | 0.74 | CYP3A4 (0.47) | CYP1A2TDP1LMNAALDH1A1GAA | |
| SCHEMBL5074691 | 0.74 | NFE2L2 (0.50) | CYP1A2LMNAHTTALDH1A1GAA | |
| Dimethylamine SCHEMBL10538055 | 0.74 | ALDH1A1 (0.45) | CYP1A2TDP1LMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423168-B2 | Reacting allyl starting compound with oxygen nucleophilic agent in presence of transition metal catalyst and monodentate phosphite | MITSUBISHI CHEMICAL CORPORATION (JP) | 2008-09-09 | — | — | US | disclosed |
| US-7241857-B2 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-07-10 | — | — | US | disclosed |
| US-7173157-B2 | Method for producing an allyl compound | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7119222-B2 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-10-10 | — | — | US | disclosed |
| US-20060106181-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-05-18 | — | — | US | disclosed |
| US-20050075518-A1 | Method for producing allyl compound, and allyl compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-04-07 | — | — | US | disclosed |
| US-20040147757-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20040092777-A1 | Method for producing allyl compound | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106181-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | AGPAT5, TST, AGPAT2 | CYP1A2 486/4885TDP1 4654/4885LMNA 4141/4885 |
| US-20040147757-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | AGPAT5, TST, AGPAT2 | CYP1A2 486/4885TDP1 4654/4885LMNA 4141/4885 |
| US-20040092777-A1 | Method for producing allyl compound | CCNT1, APEX1, REV1 | CYP1A2 1479/4885TDP1 3793/4885LMNA 4173/4885 |
| US-20050075518-A1 | Method for producing allyl compound, and allyl compound produced thereby | CCNT1, AOC3, ATL3 | CYP1A2 385/4885TDP1 4503/4885LMNA 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.